孟加拉国社区参与尼帕疫苗试验的意愿调查
本研究在孟加拉国达卡米尔普尔镇和受尼帕病毒影响的福里德布尔县开展混合方法研究,于2021年12月至2022年11月访谈了负责家庭治疗和疫苗接种决策的成年男女。共完成66次深度访谈和978次调查访谈,发现达卡受访者听说过蝙蝠传人疾病的比例(57%,272/478)高于福里德布尔(52%,262/500),参与疫苗试验的意愿(45%,217/478)也高于福里德布尔(22%,111/500);在疫情期间愿意接种研究性尼帕疫苗的比例分别为达卡75%(205/272)和福里德布尔81%(398/491)。未发现尼帕知识水平与参与疫苗试验意愿之间存在关联。
要点
- 达卡受访者听说过蝙蝠传人疾病的比例为57%(272/478),福里德布尔为52%(262/500)。
- 达卡受访者参与尼帕疫苗试验的意愿为45%(217/478),福里德布尔为22%(111/500)。
- 疫情期间愿意接种研究性尼帕疫苗的比例达卡为75%(205/272),福里德布尔为81%(398/491)。
核心结论
- 许多受访者表示愿意参与尼帕疫苗试验,尤其是在疫情期间,提示此类试验在孟加拉国可能可行。
- 鉴于对安全性和副作用的担忧,就这些问题进行清晰沟通可能有助于知情参与。
研究设计与样本
- 混合方法研究,在达卡米尔普尔镇和受尼帕病毒影响的福里德布尔县收集定性和定量数据。
- 于2021年12月至2022年11月访谈负责家庭治疗和疫苗接种决策的成年男女受访者。
- 共完成66次深度访谈和978次调查访谈。
主要发现
- 许多深度访谈受访者了解尼帕病毒,被问及是否参与尼帕疫苗试验时回答愿意、不愿意或稍后决定,决策时担忧疫苗安全性和副作用。
- 调查中,达卡米尔普尔镇受访者听说过蝙蝠传人疾病的比例为57%(272/478),福里德布尔为52%(262/500)。
- 达卡米尔普尔镇受访者参与疫苗试验的意愿为45%(217/478),福里德布尔为22%(111/500)。
- 疫情期间愿意接种研究性尼帕疫苗的比例达卡为75%(205/272),福里德布尔为81%(398/491)。
- 未发现尼帕知识水平与参与尼帕疫苗试验意愿之间存在关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Nipah virus (NiV) is a deadly zoonotic disease with pandemic potential, prioritized by the World Health Organization for research and vaccine development. Since Bangladesh has faced annual NiV outbreaks and repeated spillovers since 2001, it is likely to be the site of a Phase II vaccine trial. This study explored people's knowledge about NiV and their willingness to participate in a NiV vaccine trial in Bangladesh. METHODS: We conducted a mixed methods study, collecting qualitative and quantitative data from Mirpur township, Dhaka, and NiV-affected Faridpur District. From December 2021 to November 2022, the team interviewed adult male and female respondents responsible for household treatment and vaccination decisions. RESULTS: The team conducted 66 in-depth interviews and 978 survey interviews. Many in-depth interviewees were aware of NiV and, when asked if they would participate in a NiV vaccine trial, responded with one of three options: willing, unwilling, or would decide later. They were concerned about vaccine safety and side effects when making a decision about participation. In the survey, more respondents from Mirpur township, Dhaka, had heard about a disease transmitted from bats to people (57 %, 272/478 vs. 52 %, 262/500) and were willing to participate in a vaccine trial (45 %, 217/478 vs. 22 %, 111/500) than those from Faridpur. A high number expressed willingness to take an investigational NiV vaccine during an outbreak (Dhaka 75 %, 205/272 vs. Faridpur 81 %, 398/491 Faridpur). We did not find any association between knowledge about NiV and willingness to participate in a NiV vaccine trial. CONCLUSION: Many respondents expressed willingness to participate in a NiV vaccine trial, especially during an outbreak, suggesting that such a trial may be feasible in Bangladesh. Given concerns about safety and side effects, clear communication on these issues may support informed participation.
引用
- Nahar N, Parveen S, Gurley ES, et al. Community willingness to participate in a Nipah vaccine trial in Bangladesh. Vaccine. 2025. PMID: 40784108. doi:10.1016/j.vaccine.2025.127578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。